StockData
Rein Therapeutics, Inc. logo

Rein Therapeutics, Inc. (RNTX) stock

RNTXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 6/30
$0.36−0.00 (-0.31%)

Close on Nov 18, 2026Market cap $30.65MP/E –Yield 0.00%

Rein Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Rein Therapeutics's enterprise value was $8.35M on Nov 11, 2026, against $35.42M a year earlier. Over the last 5 years it ranged from -$20.81M to $67.18M, with a median of $15.05M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$8.35M-66.8%
2025Dec 31, 2025$25.11M-22.0%
2024Dec 31, 2024$32.18M+1712.7%
2023Dec 29, 2023$1.78M–
2022Dec 30, 2022-$14.71M–
2021Dec 31, 2021-$1.25M-104.6%
2020Dec 31, 2020$27.35M–
2019Dec 31, 2019-$8.63M–
2018Dec 31, 2018-$15.57M-115.8%
2017Dec 29, 2017$98.27M–

More Rein Therapeutics figures

See a number that looks wrong?